Choose Your Country or Region

Fluoxetine (Lilly 110140) HCl

Name: Fluoxetine (Lilly 110140) HCl
Brand: Selleck Chemicals
SKU: S1333
Rating: 5 (16 reviews)

Catalog No.S1333

For research use only.

Fluoxetine HCl (Lilly110140) is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.

Fluoxetine (Lilly 110140) HCl Chemical Structure

CAS No. 56296-78-7

Selleck's Fluoxetine (Lilly 110140) HCl has been cited by 16 publications

Purity & Quality Control

Choose Selective 5-HT Receptor Inhibitors

Related Compound Libraries

Other 5-HT Receptor Products

AZD3839^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
Xanthohumol^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
Nirogacestat (PF-03084014)^New

Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2.
WAY-100635 Maleate

WAY-100635 Maleate is a potent and selective 5-HT receptor antagonist with IC50 of 0.95 nM.
Ketanserin

Ketanserin (R41468) is a specific 5-HT2A serotonin receptor antagonist with K_i of 2.5 nM for rat and human 5-HT2A, used as an antihypertensive drug.
Asenapine maleate

Asenapine maleate (Org 5222) is a high-affinity antagonist of serotonin, norepinephrine, dopamine and histamine receptors, used for the treatment of schizophrenia and acute mania associated with bipolar disorder.
Iloperidone

Iloperidone (HP873) is a dopamine (D2)/serotonin (5-HT2) receptor antagonist, used for the treatment of schizophrenia.
Duloxetine HCl

Duloxetine HCl (LY-248686) is a serotonin-norepinephrine reuptake inhibitor with K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
Risperidone

Risperidone (R-64766) is a mutil-targeted antagonist for dopamine, serotonin, adrenergic and histamine receptors, used to treat schizophrenia and bipolar disorder.
Prucalopride Succinate

Prucalopride is a selective, high affinity 5-HT4 receptor agonist. The Ki values of prucalopride for human 5-HT(4a) and 5-HT(4b) receptor are 2.5 nM and 8 nM, respectively.

Download Inhibitor Catalog

5-HT Receptor Signaling Pathway Map

Biological Activity

Description

Fluoxetine HCl (Lilly110140) is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.

Targets

5-HT ^[1]

In vitro

Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell. ^[1] Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex. ^[2] Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus. ^[3] Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

HEK293	NV\iUmg5TnWwY4Tpc44h[XO\|YYm=	M4jMTFMxKG2rboO=	M1P0c2lvcGmkaYTpc44hd2ZiaIXtZY4hW0WUVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zic3Xyc5RwdmmwIILleZB1[WunIHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxRTBwMUZOwG0>	NY\rcVNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N\|gxPDlpPkKyPVM5ODR7PD;hQi=>
HEK293	Mk\GSpVv[3Srb36gZZN{[Xl?	M1G5bVMxKG2rboO=	M1zFRmlvcGmkaYTpc44hd2ZiaIXtZY4hVkWWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCwb4Lh[JJmdmGuaX7lJJJmfXC2YXvlJIFnfGW{IEOwJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUSuOFHPxE1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl\|OEC0PUc,OjJ7M{iwOFk9N2F-
HEK293	M{L6XGZ2dmO2aX;uJIF{e2G7	NFyxN2I{OCCvaX7z	M4i0VGlvcGmkaYTpc44hd2ZiaIXtZY4hTEGWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCmb4DhcYlv\SC{ZYXweIFs\SCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NF0yQC52zszN	MlTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7M{iwOFkoRjJ{OUO4NFQ6RC:jPh?=
mammalian cells	MU\GeY5kfGmxbjDhd5NigQ>?		MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHBwfGG\|c3n1cUBkcGGwbnXsJGhGWkdiZYjwdoV{e2WmIHnuJI1idW2jbHnhckBk\WyuczygTWM2OD1zLkWxN\|U3\|ryP	NVWxbGo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4O\|M2OTJpPkGyPFc{PTF{PD;hQi=>
JAR	NH;jZXNHfW6ldHnvckBie3OjeR?=		M2DSXmlvcGmkaYTpc44h[2:wY3XueJJifGmxbjDh[4FqdnO2IGuzTH02NUiWIIXweIFs\SCkeTDoeY1idiC\|ZYLveI9vcW5idILhcpNxd3K2ZYKgbY4hUkGUIHPlcIx{NCCLQ{WwQVAvODN{NN88US=>	NFPlb2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUKzPVY3OSd-MUWyN\|k3PjF:L3G+
K562	MXfDfZRwfG:6aXPpeJkh[XO\|YYm=		NUTKOpZkS3m2b4TvfIlkcXS7IITvJJJm\HWlZTDjbJJwdmmlIH35[YxwcWRibHX1b4VucWFiSzC1OlIh[2WubIOsJGNEPTB;MkZOwG0>	MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV{NkeyNlkoRjF3Mk[3NlI6RC:jPh?=
U937	MXHDfZRwfG:6aXPpeJkh[XO\|YYm=		M3K0fGN6fG:2b4jpZ4l1gSC2bzDy[YR2[2ViaIXtZY4hcGm\|dH;sfZRq[yCueX3wbI9u[SCXOUO3JINmdGy\|LDDDR\|UxRTN\|LkROwG0>	NV3ibIh6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWyOlczOjlpPkG1NlY4OjJ7PD;hQi=>
HEK293	MY\GeY5kfGmxbjDhd5NigQ>?		M4\aRWlvcGmkaYTpc44hd2ZiW{PIYVUuUFRidYD0ZYtmKGG2IEXIWEB1emGwc4DvdpRmeiCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwQVAvODF4zszN	NGLJ[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke1NFM2QSd-MU[3OVA{PTl:L3G+
HEK293	M3TSTWZ2dmO2aX;uJIF{e2G7		NWm1SlN5UW6qaXLpeIlwdiCxZjDERUB1emGwc4DvdpRmeiCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwQVQvPM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd3MEO1PUc,OTZ5NUCzOVk9N2F-
HEK293	Mk\zSpVv[3Srb36gZZN{[Xl?		M3TaZmlvcGmkaYTpc44hd2ZiW{PIYW5CKHWydHHr[UBifCCQQTD0doFve3CxcoTldkBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzMEBKSzVyPUWuNu69VQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd3MEO1PUc,OTZ5NUCzOVk9N2F-
HEK293	M1vvRmZ2dmO2aX;uJIF{e2G7		MnjGTY5pcWKrdHnvckBw\iCdM1jdOU1JXCC{ZYXweIFs\SCjdDC1THQhfHKjboPwc5J1\XJiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwQVAvODF4zszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd3MEO2N{c,OTZ5NUCzOlM9N2F-
HEK293	M1m2dmZ2dmO2aX;uJIF{e2G7		M3\OZ2lvcGmkaYTpc44hd2ZiW{PIYWRCKHKndYD0ZYtmKGG2IFTBJJRz[W6\|cH;yeIVzKGmwIFjFT\|I6OyClZXzsd{whUUN3ME20MlTPxE1?	NWTH[pJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3OVA{PjNpPkG2O\|UxOzZ\|PD;hQi=>
HEK293	Mo\GSpVv[3Srb36gZZN{[Xl?		NEDxXoJKdmirYnn0bY9vKG:oIGuzTH1PSSC{ZYXweIFs\SCjdDDORUB1emGwc4DvdpRmeiCrbjDISWszQTNiY3XscJMtKEmFNUC9OU4z\|ryP	M3TCbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{WwN\|Y{Lz5zNke1NFM3OzxxYU6=
Jar	MXPGeY5kfGmxbjDhd5NigQ>?		M2\US2lvcGmkaYTpc44hd2ZiW{PIYVUuUFRidYD0ZYtmKGG2IHj1cYFvKDVvSGSgeJJidnOyb4L0[ZIh\XiycnXzd4VlKGmwIFrhdkBk\WyuczygTWM2OD1yLkCzPVTPxE1?	NIj4UXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA5Pid-MU[4OVQxQDZ:L3G+
SK-N-MC	M1LqfWZ2dmO2aX;uJIF{e2G7		M4LJ[GRqe3CuYXPlcYVvfCCxZjDOMXs{UF2jbIDoZU1u\XSqeXzobZN1[W2rbnWg[pJwdSCqdX3hckBpcXO2YX3pcoUhUDNicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJHNMNU5vTVOgZ4VtdHNuIFvpQVcvO87:TR?=	Mn;0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|MEezOVgoRjF5M{C3N\|U5RC:jPh?=
CHO	NUexenkzTnWwY4Tpc44h[XO\|YYm=		M2XLU2lvcGmkaYTpc44hd2ZiaIXtZY4hTVKJIHX4dJJme3OnZDDpckBEUE9iY3XscJMh[nlid3jvcIUh[2WubDDwZZRkcCClbHHtdEB1\WOqbnnxeYUtKEmFNUC9NU42OTN3Nt88US=>	MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2NEizOFIoRjF6NES4N\|QzRC:jPh?=
HEK293	MXrGeY5kfGmxbjDhd5NigQ>?		NHznW3RKdmirYnn0bY9vKG:oIIPldo91d26rbjD1dJRic2ViYYSgbJVu[W5iU1XSWEBqdiCqdX3hckBJTUt{OUOgZ4VtdHNuIFnDOVA:OC5yNEhOwG0>	Mk\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUCzOlkoRjF6NUWwN\|Y6RC:jPh?=
HEK293	M4\uR2Z2dmO2aX;uJIF{e2G7		NWTkN41qUW6qaXLpeIlwdiCxZjDuc5JmeGmwZYDodolv\SC3cIThb4Uh[XRiaIXtZY4hVkWWIHnuJIh2dWGwIFjFT\|I6OyClZXzsd{whUUN3ME2y{txO	NVeyUnJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OVA{PjlpPkG4OVUxOzZ7PD;hQi=>
HEK293	NYmxV2RSTnWwY4Tpc44h[XO\|YYm=		M4PJRWlvcGmkaYTpc44hd2ZiZH;wZY1qdmVidYD0ZYtmKGG2IHj1cYFvKESDVDDpckBpfW2jbjDISWszQTNiY3XscJMtKEmFNUC9Ou69VQ>?	MkWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUCzOlkoRjF6NUWwN\|Y6RC:jPh?=
JAR	NUPkfXFmTnWwY4Tpc44h[XO\|YYm=		Mm\uTY5pcWKrdHnvckBw\iB3SGSgeZB1[WunIHH0JIh2dWGwIGPFVnQh\XiycnXzd4VlKGmwIHj1cYFvKEqDUjDj[YxteyxiSVO1NF0xNjByOUVOwG0>	M1HLUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUW3OlA5Lz5zOEW1O\|YxQDxxYU6=
HEK	NHHONo1HfW6ldHnvckBie3OjeR?=		Moi5TY5pcWKrdHnvckBw\iC\|ZYLveI9vcW5idYD0ZYtmKGG2IHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKEiHSzDj[YxteyxiSVO1NF0xNjB2N988US=>	NXfnZWN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2Olc{ODlpPkG4OlY4OzB7PD;hQi=>
HEK	NH;GWlZHfW6ldHnvckBie3OjeR?=		NVrwUZJnUW6qaXLpeIlwdiCxZjDuc5JmeGmwZYDodolv\SC3cIThb4Uh[XRiaIXtZY4hVkWWIHX4dJJme3OnZDDpckBJTUtiY3XscJMtKEmFNUC9Nu69VQ>?	MmXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkezNFkoRjF6Nk[3N\|A6RC:jPh?=
HEK	Mm\ZSpVv[3Srb36gZZN{[Xl?		MYHJcohq[mm2aX;uJI9nKGSxcHHtbY5mKHWydHHr[UBifCCqdX3hckBFSVRiZYjwdoV{e2WmIHnuJGhGUyClZXzsd{whUUN3ME22{txO	M2riVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[3N\|A6Lz5zOE[2O\|MxQTxxYU6=
JAR	Mo\VSpVv[3Srb36gZZN{[Xl?		NHXWdWFKdmirYnn0bY9vKG:oIIPldo91d26rbjD1dJRic2ViYYSgbJVu[W5iU1XSWEBmgHC{ZYPz[YQhcW5iSlHSJINmdGy\|LDDJR\|UxRTBwMEJOwG0>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd5MUmxOkc,OTh5N{G5NVY9N2F-
MDCK	M1jDOmZ2dmO2aX;uJIF{e2G7		MorITY5pcWKrdHnvckBw\iCwb4LldIlv\XCqcnnu[UB2eHSja3WgZZQhcHWvYX6gUmVVKGW6cILld5Nm\CCrbjDNSGNMKGOnbHzzMEBKSzVyPUCuOVY{\|ryP	M2jPSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{exPVE3Lz5zOEe3NVkyPjxxYU6=
Jar	NXnFOFlyTnWwY4Tpc44h[XO\|YYm=		NUK2TZJUUW6qaXLpeIlwdiCxZjC1MWhVKHS{YX7zdI9zfGW{LX3l[IlifGWmIGuzTH02UFRidYD0ZYtmKGmwIHj1cYFvKEqjcjDj[YxteyxiSVO1NF0xNjB\|OUVOwG0>	NGjuSJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEizOFE5QCd-MUi4N\|QyQDh:L3G+
JAR	M33hZmZ2dmO2aX;uJIF{e2G7		MoTnTY5pcWKrdHnvckBw\iC\|ZYLveI9vcW5idYD0ZYtmKGG2IHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKEqDUjDj[YxteyxiSVO1NF0xNjByOUVOwG0>	NYnxS\|FYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5OVExOjBpPkG4PVUyODJyPD;hQi=>
HEK293	MVTGeY5kfGmxbjDhd5NigQ>?		M{\jU2Rqe3CuYXPlcYVvfCCxZjDbNVI2UV2UVFm1OUBnem:vIHj1cYFvKHKnY3;tZolv[W62IGPFVnQh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{whU2l;MD6wNFEy\|ryP	MoDGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyMUS4PFgoRjF7MEG0PFg5RC:jPh?=
HEK293	MV3GeY5kfGmxbjDhd5NigQ>?		NHz6UHlKdmirYnn0bY9vKG:oIGuzTH02UFRiZoLvcUBpfW2jbjDy[YNwdWKrbnHueEBUTVKWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNuIFnDOVA:OC5yMEhOwG0>	NVzIbopKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNVQ5QDhpPkG5NFE1QDh6PD;hQi=>
HEK293	NFjL[IFHfW6ldHnvckBie3OjeR?=		NUL3UYZwUW6qaXLpeIlwdiCxZjDbN2heVkViZoLvcUBpfW2jbjDy[YNwdWKrbnHueEBPTVRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyxiSVO1NF0yNjB{zszN	NX\HcVZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNVQ5QDhpPkG5NFE1QDh6PD;hQi=>
HEK293	NXfje\|V5TnWwY4Tpc44h[XO\|YYm=		M2D0XWRqe3CuYXPlcYVvfCCxZjDbNVI2UV2UVFm1OUBnem:vIHj1cYFvKHKnY3;tZolv[W62IF7FWEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzMEBMcT1zLkW2{txO	MmO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyMUS4PFgoRjF7MEG0PFg5RC:jPh?=
HEK293	NVy1WWpvTnWwY4Tpc44h[XO\|YYm=		MnvkSIl{eGyjY3Xt[Y51KG:oIGuxNlVKZVKWSUW1JIZzd21iaIXtZY4hemWlb33ibY5idnRiRFHUJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOsJGtqRTZwNkhOwG0>	M36zWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEG0PFg5Lz5zOUCxOFg5QDxxYU6=
HEK293	NEn1OYdHfW6ldHnvckBie3OjeR?=		M2DlfGlvcGmkaYTpc44hd2ZiW{PIYWRCKG[{b32gbJVu[W5icnXjc41jcW6jboSgSGFVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMtKEmFNUC9NVkvPc7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTBzNEi4PEc,OTlyMUS4PFg9N2F-
HEK293	MnnCSpVv[3Srb36gZZN{[Xl?		NWnQVmh3TGm\|cHzhZ4Vu\W62IH;mJHsyOjWLXWLUTU02PSCocn;tJIh2dWGwIILlZ49u[mmwYX70JHNGWlRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCNaU2wMlAxOTIQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NkWwNkc,OTl{NU[1NFI9N2F-
HEK293	NF7lcYdHfW6ldHnvckBie3OjeR?=		MmDqSIl{eGyjY3Xt[Y51KG:oIGuzTH1{\XKxdH;ubY4h\nKxbTDoeY1idiC{ZXPvcYJqdmGwdDDTSXJVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3ME2wMlAxPzQQvF2=	MnzKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NU[1NFIoRjF7MkW2OVAzRC:jPh?=
HEK293	NHvGe\|FHfW6ldHnvckBie3OjeR?=		M{H2W2Rqe3CuYXPlcYVvfCCxZjDbN2hedm:{ZYDpcoVxcHKrbnWg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCQRWSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR\|UxRTFwMENOwG0>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NkWwNkc,OTl{NU[1NFI9N2F-
HEK293	M17UVGZ2dmO2aX;uJIF{e2G7		M4DYbWRqe3CuYXPlcYVvfCCxZjDbNVI2UV2UVFmtOVUh\nKxbTDoeY1idiC{ZXPvcYJqdmGwdDDOSXQh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcT1zLkW2{txO	M3PkXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW2OVAzLz5zOUK1OlUxOjxxYU6=
HEK293	Mn3hSpVv[3Srb36gZZN{[Xl?		M2DNdGRqe3CuYXPlcYVvfCCxZjDbNVI2UV2UVFmtOVUh\nKxbTDoeY1idiC{ZXPvcYJqdmGwdDDERXQh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{BjgSC\|Y3nueIltdGG2aX;uJINwfW62aX7nMEBMcT14Lk[3{txO	NVXYPJA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVY2ODJpPkG5NlU3PTB{PD;hQi=>
HEK293	M2f1NGZ2dmO2aX;uJIF{e2G7		NXjIUpRRTGm\|cHzhZ4Vu\W62IH;mJHs{UF2mb4DhcYlv\SCocn;tJIh2dWGwIILlZ49u[mmwYX70JGRCXCCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUC9NVkvPc7:TR?=	M4rke\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW2OVAzLz5zOUK1OlUxOjxxYU6=
JAR	NGfmS5ZHfW6ldHnvckBie3OjeR?=		NWLKeXNTUW6qaXLpeIlwdiCxZjDz[ZJwfG:waX6geZB1[WunIHH0JIh2dWGwIGPFVnQh\XiycnXzd4VlKGmwIHj1cYFvKEqDUjDj[YxteyxiSVO1NF0xNjBzzszN	NYDMfYQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNlk{OTNpPkG5N\|I6OzF\|PD;hQi=>
MDCK-Net6	MXjGeY5kfGmxbjDhd5NigQ>?		MnnwTY5pcWKrdHnvckBw\iCwb4LldIlv\XCqcnnu[UB2eHSja3WgZZQhcHWvYX6gUmVVKGW6cILld5Nm\CCrbjDNSGNMNU6ndE[gZ4VtdHNuIFnDOVA:OC53NkROwG0>	NHS5[WE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOyPVMyOyd-MUmzNlk{OTN:L3G+
JAR	NVLWPYVKTnWwY4Tpc44h[XO\|YYm=		NEfKRolKdmirYnn0bY9vKG:oIIPldo91d26rbjD1dJRic2ViYYSgbJVu[W5iU1XSWEBmgHC{ZYPz[YQhcW5iSlHSJINmdGy\|LDDJR\|UxRTBwMEC5OO69VQ>?	NHi2[GI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zNlEyOCd-MUm2N\|IyOTB:L3G+
JAR	NF;TVXlHfW6ldHnvckBie3OjeR?=		NH3uSmVKdmirYnn0bY9vKG:oIHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKEqDUjDj[YxteyxiSVO1NF0xNjByOUVOwG0>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdzM{GwOkc,OTl5MUOxNFY9N2F-
JAR	M4LMNmZ2dmO2aX;uJIF{e2G7		MVrJcohq[mm2aX;uJI9nKFt\|SG3ofYRzd3i7dIL5dJRidWmwZTDjdoVifGmwaX7lJJN2dG[jdHWgeZB1[WunIHH0JIh2dWGwIGPFVnQh\XiycnXzd4VlKGmwIHj1cYFvKEqDUjDj[YxteyxiSVO1NF0xNjByOUVOwG0>	MkO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5MkK1NlUoRjF7N{KyOVI2RC:jPh?=
HEK293	MVzGeY5kfGmxbjDhd5NigQ>?		MXHEbZNxdGGlZX3lcpQhd2ZiW1mxNlVeWlSLLUW1JIZzd21iaIXtZY4hW0WUVDD0doFve2[nY4Tl[EBqdiCqdX3hckBJTUt{OUOgZ4VtdHNuIFnDOVA:OC5yMEK1{txO	NVzZPYZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwN\|Q4QTNpPkKwNFM1Pzl\|PD;hQi=>
JAR	NVe1XG1tTnWwY4Tpc44h[XO\|YYm=		NV75bZFGUW6qaXLpeIlwdiCxZjDz[ZJwfG:waX6geZB1[WunIHH0JIh2dWGwIGPFVnQh\XiycnXzd4VlKGmwIHj1cYFvKEqDUjDj[YxteyxiSVO1NF0xNjByOUVOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MUi2OEc,OjBzM{G4OlQ9N2F-
JAR	NWfIeId5TnWwY4Tpc44h[XO\|YYm=		NGT3WnRKdmirYnn0bY9vKG:oIHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKGi3bXHuJGpCWiClZXzsd{whUUN3ME2wMlAxQTUQvF2=	NGjVWZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO3PFM1Pyd-MkCzO\|g{PDd:L3G+
JAR	NHXXdHRHfW6ldHnvckBie3OjeR?=		NYDMT5lEUW6qaXLpeIlwdiCxZjDTSXJVNW2nZHnheIVlKHOncn;0c45qdiC3cIThb4UhcW5iaIXtZY4hUkGUIHPlcIx{NCCLQ{WwQVAvODB7NN88US=>	MlGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NkKyNVEoRjJyNE[yNlEyRC:jPh?=
BESM	M2\MfmFvfGm2conwZY5we2:vYXygZZN{[Xl?	MoLGPFghcHK\|	MYTBcpRqfHK7cHHuc5NwdWGuIHHjeIl3cXS7IHHnZYlve3RiVIL5dIFvd3OxbXGgZ5J2gmliYX3hd5Rq\2:2ZYOgbY5n\WO2ZXSgbY4hSkWVTTDj[YxteyCvZXHzeZJm\CCjZoTldkA5QCCqcoOgdI9{fGmwZnXjeIlwdiCkeTDIWHMh[XO\|YYmsJGVEPTB;N988US=>	NH3OUYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW0O\|gyQSd-MkC1OFc5OTl:L3G+
BESM	M3vk[mN6fG:2b4jpZ4l1gSCjc4PhfS=>	MVe4PEBpenN?	MmW0R5l1d3SxeHnjbZR6KGGpYXnud5QhSkWVTTDj[YxteyCjZoTldkA5QCCqcoOgZpkhUFSVIHHzd4F6NCCHQ{WwQVE3\|ryP	NGnXO3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEW0O\|gyQSd-MkC1OFc5OTl:L3G+
HEK293	MmLmSpVv[3Srb36gZZN{[Xl?		MlzUSIl{eGyjY3Xt[Y51KG:oIGuzTH0h[XO2ZX3pfo9t\SCocn;tJIh2dWGwIILlZ49u[mmwYX70JGVTTyClaHHucoVtKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMtKEmFNUC9N{4y\|ryP	NYPBRnBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2N\|c3OzVpPkKwOlM4PjN3PD;hQi=>
HEK293	M3rtSWZ2dmO2aX;uJIF{e2G7		MWXJcohq[mm2aX;uJI9nKHOncn;0c45qdiC{ZYXweIFs\SCjdDDoeY1idiCVRWLUJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOsJGlEPTB;MD6wNFMy\|ryP	M13FZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyN{K0NVU{Lz5{MEeyOFE2OzxxYU6=
HEK293	NXPaWG85TnWwY4Tpc44h[XO\|YYm=		M1fNT2lvcGmkaYTpc44hd2ZiW{PIYZNmem:2b37pckBz\XWydHHr[UBifCCqdX3hckBUTVKWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByNUNOwG0>	NUTB[G8xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVMzPzNpPkKxNFk{Ojd\|PD;hQi=>
LLC-PK1	MYLGeY5kfGmxbjDhd5NigQ>?		MX;Jcohq[mm2aX;uJI9nKFt\|SG3z[ZJwfG:waX6gdoV2eHSja3WgZZQhcHWvYX6gdoVkd22kaX7hcpQhW0WUVDDlfJBz\XO\|ZXSgbY4hVEyFLWDLNUBk\WyuczDifUBtcXG3aXSgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByNUCxNu69VQ>?	M{TydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{GwOlEzLz5{MUOxNFYyOjxxYU6=
HEK293	MornSpVv[3Srb36gZZN{[Xl?		Mki1TY5pcWKrdHnvckBw\iC\|ZYLveI9vcW5icnX1dJRic2ViYYSgV2VTXCCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwQVAvODB3MEGy{txO	NFTyWFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUezPVk{PSd-MkG3N\|k6OzV:L3G+
JAR	MX\GeY5kfGmxbjDhd5NigQ>?		NYnydpBlUW6qaXLpeIlwdiCxZjDoeY1idiCVRWLUJIV5eHKnc4Pl[EBqdiCMQWKgZ4VtdHNiYYPz[ZN{\WRiYYOgd4Vzd3SxbnnuJJVxfGGtZTygTWM2OD1yLkCwPVTPxE1?	NIDoUJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUmxOlQzOSd-MkG5NVY1OjF:L3G+
HEK293	M{nGbGZ2dmO2aX;uJIF{e2G7		MoDqTY5pcWKrdHnvckBw\iCqdX3hckBUTVKWLX3l[IlifGWmIIPldo91d26rbjDy[ZVxfGGtZTDpckBJTUt{OUOgZ4VtdHNuIFXDOVA:OC5yMEK3{txO	NXi5VIs2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5Nlc3PDVpPkKxPVI4PjR3PD;hQi=>
CHO	MmW0SpVv[3Srb36gZZN{[Xl?		M3rUVWlvcGmkaYTpc44hd2ZicnH0JJZwdHSjZ3Wt[4F1\WRiSzDjbIFvdmWuIEOuNUBmgHC{ZYPz[YQhcW5iQ1jPJINmdGy\|IHL5JJBifGOqIHPsZY1xKGG\|c3H5MEBKSzVyPUGzMlHPxE1?	M2PDdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUKxNFk3Lz5{M{GyNVA6PjxxYU6=
HEK293	NFj6RYNHfW6ldHnvckBie3OjeR?=	MnfmOlAhdWmwcx?=	NVXQfYFoTGm\|cHzhZ4Vu\W62IH;mJHs{UF2SYYLvfIV1cW6nIH\yc40hcHWvYX6gdoVkd22kaX7hcpQhW0WUVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHmeIVzKDZyIH3pcpMtKEurPUCuNFAyPM7:TR?=	Ml7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MEOwPFIoRjJ\|NECzNFgzRC:jPh?=
HEK293	MoGzSpVv[3Srb36gZZN{[Xl?	NWrlWmcxPjBibXnudy=>	M3j1OWRqe3CuYXPlcYVvfCCxZjDbN2heWGG{b4jleIlv\SCocn;tJIh2dWGwIILlZ49u[mmwYX70JHNGWlRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkA3OCCvaX7zMEBKSzVyPUCuNFA5Ps7:TR?=	NHLtblc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SwN\|A5Oid-MkO0NFMxQDJ:L3G+
HEK293	NF;RT5dHfW6ldHnvckBie3OjeR?=	NXTj[21YOTBibXnudy=>	M4q0c2lvcGmkaYTpc44hd2ZiW{PIYVUuUFRidYD0ZYtmKGG2IHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEGwJI1qdnNicILpc5IhfG9ic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRibXnud{BjgSCITFnQVkBie3OjeTygT4k:OC5yOUlOwG0>	NIPycHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNlQ1PSd-MkO2NFI1PDV:L3G+
HEK293	NVPhN3JwTnWwY4Tpc44h[XO\|YYm=	M{CwU\|ExKG2rboO=	MWfJcohq[mm2aX;uJI9nKFt\|SG21MWhVKHWydHHr[UBifCCqdX3hckBUTVKWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzMDDtbY5{KHC{aX;yJJRwKHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KG2rboOgZpkhTkyLUGKgZZN{[XluIFnDOVA:OC5{OEG4OO69VQ>?	NUSwPZZ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFI1PDVpPkKzOlAzPDR3PD;hQi=>
HEK293	Mn23SpVv[3Srb36gZZN{[Xl?	M325bVExKG2rboO=	MXLJcohq[mm2aX;uJI9nKFt\|SG3uc5JmeGmwZYDodolv\SC3cIThb4Uh[XRiaIXtZY4hVkWWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzMDDtbY5{KHC{aX;yJJRwKHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KG2rboOgZpkhTkyLUGKgZZN{[XluIFvpQVEvOzl2zszN	M3ToPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCyOFQ2Lz5{M{[wNlQ1PTxxYU6=
HEK293	NYPNb4JVTnWwY4Tpc44h[XO\|YYm=	NX\BfWJvOTBibXnudy=>	MYXJcohq[mm2aX;uJI9nKFt\|SG3kc5BidWmwZTD1dJRic2ViYYSgbJVu[W5iRFHUJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxNEBucW6\|IIDybY9zKHSxIIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB2IH3pcpMh[nliRlzJVHIh[XO\|YYmsJGtqRTNwN{[0{txO	M2fGeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCyOFQ2Lz5{M{[wNlQ1PTxxYU6=
HEK293	M3fCfmZ2dmO2aX;uJIF{e2G7	NH;0R2YyOCCvaX7z	NEXDR\|dKdmirYnn0bY9vKG:oIGuzTH1vd3KncHnu[ZBpemmwZTD1dJRic2ViYYSgbJVu[W5iTlXUJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxNEBucW6\|IIDybY9zKHSxIIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB2IH3pcpMh[nliRlzJVHIh[XO\|YYmsJGlEPTB;Nj6zNFk2P87:TR?=	M4ey[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCyOFQ2Lz5{M{[wNlQ1PTxxYU6=
HEK293	NE[zbJlHfW6ldHnvckBie3OjeR?=	NWnoNYJLOTBibXnudy=>	MYXJcohq[mm2aX;uJI9nKFt\|SG3kc5BidWmwZTD1dJRic2ViYYSgbJVu[W5iRFHUJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCxNEBucW6\|IIDybY9zKHSxIIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB2IH3pcpMh[nliRlzJVHIh[XO\|YYmsJGlEPTB;OT6xNlAyOc7:TR?=	M1y4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCyOFQ2Lz5{M{[wNlQ1PTxxYU6=
HEK293	NFL0R4NHfW6ldHnvckBie3OjeR?=		NEHDN2hFcXOybHHj[Y1mdnRib3[gX\|NJZWmvaYDyZY1qdiCocn;tJIh2dWGwIILlZ49u[mmwYX70JHNGWlRib4\ldk1mgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzMEBKSzVyPUCuNFA4Os7:TR?=	NIfEZY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxNlE5OSd-MkSwNVIyQDF:L3G+
HEK293	NGTOT5RHfW6ldHnvckBie3OjeR?=	M1y0W\|E2KG2rboO=	NELUTGVKdmirYnn0bY9vKG:oIIPldo91d26rbjDy[ZVxfGGtZTDheEBpfW2jbjDTSXJVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNVUhdWmwczDifUBndHWxcnXzZ4Vv[2VibnX1do91emGwc33peJRmeiC2cnHud5BwenSncjDhd5NigSxiSVO1NF0xNjF3zszN	MojDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7N{SzOFAoRjJ2OUe0N\|QxRC:jPh?=
HEK293	NIrTbFlHfW6ldHnvckBie3OjeR?=	MV:xOUBucW6\|	NYPXOlJlUW6qaXLpeIlwdiCxZjDuc5JmeGmwZYDodolv\SC{ZYXweIFs\SCjdDDoeY1idiCQRWSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDh[pRmeiBzNTDtbY5{KGK7IH\seY9z\XOlZX7j[UBv\XW{b4TyZY5{dWm2dHXyJJRz[W6\|cH;yeIVzKGG\|c3H5MEBKSzVyPUSuOFHPxE1?	NIDBUFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3OFM1OCd-MkS5O\|Q{PDB:L3G+
HEK293	M2fmPWZ2dmO2aX;uJIF{e2G7	MnjCNVUhdWmwcx?=	MnvKTY5pcWKrdHnvckBw\iCGQTDy[ZVxfGGtZTDheEBpfW2jbjDERXQh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{Bi\nSncjCxOUBucW6\|IHL5JIZtfW:{ZYPj[Y5k\SCwZYXyc5Rz[W6\|bXn0eIVzKHS{YX7zdI9zfGW{IHHzd4F6NCCLQ{WwQVE5NjUQvF2=	NIXqPGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3OFM1OCd-MkS5O\|Q{PDB:L3G+
HEK293	M2TFZmZ2dmO2aX;uJIF{e2G7	MnOxNVUhdWmwcx?=	NGPIeYVKdmirYnn0bY9vKG:oIHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDheEBqdmO3YnH0[YQh\m:{IEG1JI1qdnNiYomgcoV2em:2cnHud41qfHSncjDy[ZVxfGGtZTDhd5NigSxiSVO1NF0xNjF3zszN	M2m4RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKxOlU3Lz5{NUKyNVY2PjxxYU6=
HEK293	NEPVeFlHfW6ldHnvckBie3OjeR?=	M1q1eFE2KG2rboO=	NFfS[oVKdmirYnn0bY9vKG:oIHj1cYFvKE6HVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHH0JIlv[3WkYYTl[EBnd3JiMUWgcYlveyCkeTDu[ZVzd3S{YX7zcYl1fGW{IILleZB1[WunIHHzd4F6NCCLQ{WwQVQvPDIQvF2=	NG[xSXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNVY2Pid-MkWyNlE3PTZ:L3G+
HEK293	NVrHNmVOTnWwY4Tpc44h[XO\|YYm=	M3zwZVE2KG2rboO=	MmixTY5pcWKrdHnvckBw\iCqdX3hckBFSVRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjdDDpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh[nlibnX1do91emGwc33peJRmeiC{ZYXweIFs\SCjc4PhfUwhUUN3ME2xPE41\|ryP	M3TSR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKxOlU3Lz5{NUKyNVY2PjxxYU6=
HEK293	NHfkV3lHfW6ldHnvckBie3OjeR?=		M1fadmlvcGmkaYTpc44hd2Zib3[gbJVu[W5iVGLFT\|Eh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4hidm6nbDDjeZJz\W62czygTWM2OD1zNN88US=>	NYfO[INWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PFgxPDVpPkK2OVg5ODR3PD;hQi=>
tsA201	NETiPWxHfW6ldHnvckBie3OjeR?=		MmO4TY5pcWKrdHnvckBw\iCxZjDoeY1idiCWUlXLNUBmgHC{ZYPz[YQhcW5idIPBNlAyKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDjbIFvdmWuIHP1dpJmdnS\|LDDJR\|UxRTF7zszN	NWO3bHZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PFgxPDVpPkK2OVg5ODR3PD;hQi=>
OHS-50	NIDzcYVyUFSVIHHzd4F6		MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MmDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	M2DUZ5FJXFNiYYPzZZk>		Mny2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	NYDq[5BwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MkTnRY51cX[rcnHsJIF{e2G7	NYTRPHdVPSCvaX7z	NHPvN49CdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBGdnSncn;2bZJ2eyCGNkigWXMwU1lxMUStNVg6PTNiaX7m[YN1\WRiaX6gbJVu[W5iUlSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC4aYL1d{1qdmS3Y3XkJIN6fG:yYYTobYMh\W[oZXP0JIlv[3WkYYTl[EBnd3JiNTDtbY5{KHWwZHXyJJNp[WurbnegZ49v\Gm2aX;uJIFv\CCvZXHzeZJm\CCjZoTldkA{KGSjeYOgZpkhdmW3dILhcEBz\WRiZInlMYJie2WmIIDoc5RwdWW2cnnjJI1mfGhuIFXDOVA:Oc7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODlzMkm0OEc,OzB7MUK5OFQ9N2F-
RD	NVS2[Ix5S3m2b4TvfIlkcXS7IHHzd4F6	MVWzJIRigXN?	NW\Yb5JNS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWkRiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JI5mfXS{YXygdoVlKGS7ZT3iZZNm\CCyaH;0c41mfHKrYzDt[ZRpd2RuIFPDOVA:OTFwOd88US=>	M4O0blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyOUGyPVQ1Lz5\|MEmxNlk1PDxxYU6=
Huh7	NYnr[Ix2SW62aY\pdoFtKGG\|c3H5		MWTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDESW5XOiCrbn\lZ5Rm\CCrbjDoeY1idiCKdXi3JINmdGy\|IHL5JJFTXC2SQ2KgZY5idHm\|aYOsJGlEPTB;MD6zPO69VQ>?	NIPRUWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUGyPFQ1Pyd-M{GxNlg1PDd:L3G+

Click to View More Cell Line Experimental Data

In vivo

Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague–Dawley rats. ^[1] Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone. ^[5]

Protocol (from reference)

References

+ Expand

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight	345.79
Formula	C₁₇H₁₈F₃NO.HCl
CAS No.	56296-78-7
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl

Download Fluoxetine (Lilly 110140) HCl SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04676139	Recruiting	Drug: Fluoxetine\|Drug: Placebo	Nocturnal Enuresis	Mansoura University	July 1 2020	Phase 3
NCT01615055	Withdrawn	Drug: Fluoxetine\|Other: Placebo	Cognitive Dysfunction	University of California Los Angeles\|City of Hope Medical Center	June 2018	Early Phase 1
NCT03390933	Recruiting	Drug: Fluoxetine	Depression\|Hemodialysis-Induced Symptom	MetroHealth Medical Center	March 1 2018	Phase 4
NCT02767999	Recruiting	Drug: Fluoxetine\|Drug: Placebo\|Radiation: fMRI	Stroke	University Hospital Toulouse	February 27 2017	Phase 4
NCT03476525	Recruiting	Drug: Fluoxetine	Obesity Morbid	Norwegian University of Science and Technology\|St. Olavs Hospital\|Volvat Medisinsk Senter Stokkan\|Namsos Hospital\|Alesund Hospital	November 2 2016	--
NCT02063425	Terminated	Drug: Fluoxetine\|Drug: Placebo of fluoxetine	Cerebral Infarction	Centre Hospitalier St Anne	February 2014	Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):